No Monitoring needed if there are no Storage Conditions on the Outer Packaging?
Recommendation

8 September 2026
Basel, Switzerland
Specifics in the Distribution of Medicinal Products
"Is it acceptable that storage conditions are not monitored for medicinal products which do not have any predefined storage conditions on the outer packaging?" This question was the first GDP-related question being published along with an answer in the Q&A Section of EMA's website.
And EMA gives a clear answer: "No".
The justification is based on the Guideline on declaration of storage conditions (CPMP/QWP/609/96 Rev. 2). If a marketing authorisation holder (MAH) does not want to include storage conditions on the labelling, the MAH at least will need to provide stability data for storage conditions at 25°C / 60% relative humidity (RH), or 30°C / 65% RH (long term) and 40°C / 75% RH (accelerated). This stability data is based on the temperature and humidity conditions of climate zone I (temperate) and II (Mediterranean/subtropical) in Europe.
As a consequence, controls should be in place to maintain conditions relevant to these climate zones, if no labelling statement is given. This means that the temperature should be monitored during storage and transport.
Related GMP News
11.08.2026GDP for APIs: APIC Publishes Updated "How to Do" Document
11.08.2026Where to Find Information on UK Wholesale Authorisations
11.08.2026Call for Presentations: GDP Forum 2027 in Berlin
11.08.2026Questions and Answers from the ECA Webinar "GDP Update 2026" - Part 5
14.07.2026USP Proposes to Revise the Definition of Controlled Room Temperature in Chapter <659>
14.07.2026GDP in Hong Kong: Authority Provides Additional Information


